Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2007

View Archived Issues

AstraZeneca identifies a novel class of small molecule UMP kinase inhibitors

Odanacatib's preclinical profile reported by Merck & Co.

Novexel's NXL-101 and NXL-104 evaluated in healthy volunteers

MK-0429 activity seen in animals and humans with bone metastases

Combination of CAPOX-B and cetuximab feasible in colorectal cancer

Studies provide data on S-013420 characteristics in vitro and in pneumonia patients

VIA receives financial support for ACS substudy of VIA-2291

First patient dosed in phase III trial of AGI-003 for IBS-D

Orexo adds two new projects to its development pipeline

FDA special protocol assessment assigned to atacicept pivotal trial

New renin inhibitor SPP-676 begins phase I clinical trials

Two phase II clinical trials launched for GFT-505

Positive phase II results reported for Lu-AA-21004 in major depression

Roche files a clinical trial application for Genmab antibody

Long-acting, nonopiate analgesic drug enters THA trial

Post-infarct cardiac healing of Corgentin to be evaluated in NIH trial

New agreement on development and commercialization of THR-174

Novel treatment options for obesity described in recent Servier and Pharmacopeia patents

New agents for treating gastrointestinal disorders reported in recent patents

Four phase I/II clinical trials commence for AEG-35156

Dosing begins in phase III registration studies for clevudine

Acusphere progresses toward NDA filing for Imagify

Enrollment commences for phase I 18F-AV-133 proof-of-concept study

MacroChem acquires rights to pexiganan

Ortho-Clinical Diagnostics introduces improved sensitivity troponin I assay

Phase I results reported for rabies antibody cocktail

New anticancer agents reported in recent patents

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...